| __timestamp | Madrigal Pharmaceuticals, Inc. | Teva Pharmaceutical Industries Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 15746000 | 5078000000 |
| Thursday, January 1, 2015 | 13392000 | 4717000000 |
| Friday, January 1, 2016 | 9290000 | 5096000000 |
| Sunday, January 1, 2017 | 7672000 | 4986000000 |
| Monday, January 1, 2018 | 15293000 | 4214000000 |
| Tuesday, January 1, 2019 | 22648000 | 3806000000 |
| Wednesday, January 1, 2020 | 21864000 | 3671000000 |
| Friday, January 1, 2021 | 37318000 | 3528000000 |
| Saturday, January 1, 2022 | 48130000 | 3445000000 |
| Sunday, January 1, 2023 | 108146000 | 3498000000 |
| Monday, January 1, 2024 | 3702000000 |
Unleashing insights
In the competitive world of pharmaceuticals, operational efficiency is key. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Teva Pharmaceutical Industries Limited and Madrigal Pharmaceuticals, Inc. from 2014 to 2023. Teva, a giant in the industry, consistently reported SG&A expenses in the billions, peaking at approximately $5.1 billion in 2016. However, a notable decline of about 32% was observed by 2023, reflecting strategic cost-cutting measures.
Conversely, Madrigal Pharmaceuticals, a smaller player, showed a different trend. Starting with modest expenses in 2014, Madrigal's SG&A costs surged by over 580% by 2023, reaching around $108 million. This increase highlights Madrigal's aggressive expansion and investment in growth. The contrasting trajectories of these companies underscore the diverse strategies in the pharmaceutical sector, where size and market position dictate financial priorities.
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Madrigal Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and Bio-Techne Corporation
Teva Pharmaceutical Industries Limited vs Viking Therapeutics, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Teva Pharmaceutical Industries Limited and Protagonist Therapeutics, Inc.
Comparing SG&A Expenses: Teva Pharmaceutical Industries Limited vs Bausch Health Companies Inc. Trends and Insights
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs Mesoblast Limited
Breaking Down SG&A Expenses: Teva Pharmaceutical Industries Limited vs Iovance Biotherapeutics, Inc.
Teva Pharmaceutical Industries Limited vs Celldex Therapeutics, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Blueprint Medicines Corporation or Madrigal Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Madrigal Pharmaceuticals, Inc. and CRISPR Therapeutics AG
Comparing SG&A Expenses: Madrigal Pharmaceuticals, Inc. vs Veracyte, Inc. Trends and Insights
Comparing SG&A Expenses: Madrigal Pharmaceuticals, Inc. vs HUTCHMED (China) Limited Trends and Insights